Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2014

Open Access 01-12-2014 | Research article

Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model

Authors: Monika Vicenova, Katerina Nechvatalova, Katarina Chlebova, Zdenka Kucerova, Lenka Leva, Hana Stepanova, Martin Faldyna

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Login to get access

Abstract

Background

This study aims to investigate the anti-inflammatory effect of biologically active phospholipids (BAP) used in preparations for clinical practice in humans. Until date, except anti-neoplastic ability, little is known about anti-inflammatory property of the phospholipids.

Methods

While the course of bacterially induced acute pneumonia and markers of inflammation were studied in in vivo system in pigs orally supplemented with BAP, the pro- and anti-inflammatory response of lipopolysaccharide-stimulated porcine monocyte-derived macrophages to 24 h- and 48 h-treatmeant by BAP was investigated in in vitro system. In vivo, the animal health status was monitored and pro-inflammatory IL-1β and IL-8 in sera were detected by ELISA during the experiment, while bronchoalveolar lavage fluids (BALF) and the lungs were examined post-mortem. Total and differential counts of white blood cell (WBC) were determined in blood and BALF. In vitro, mRNA expression of pro-inflammatory (TNF-α, IL-1β, CXCL10) and anti-inflammatory (IL-10 and Arg1) cytokines, and level of activated caspase 1 and phosphorylated protein kinase C epsilon (pPKCϵ), were studied using qRT-PCR and Western blot, respectively. For the purposes of both systems, 6 animals were used in each of the BAP-supplemented and the control groups.

Results

In vivo, BAP had a positive influence on the course of the disease. The immunomodulatory effects of BAP were confirmed by lower levels of IL-1β, IL-8, and a lower WBC count in the supplemented group in comparison with the control group. A lower percentage of lung parenchyma was affected in the supplemented group comparing to the control group (on average, 4% and 34% of tissue, respectively). In vitro, BAP suppressed mRNA expression of mRNA for IL-10 and all pro-inflammatory cytokines tested. This down-regulation was dose- and time-dependent. Arg1 mRNA expression remained unaffected. Further dose- and time-dependent suppression of the activated caspase 1 and pPKCϵ was detected in macrophages when treated with BAP.

Conclusions

Our results demonstrate that BAP has anti-inflammatory and immunomodulatory properties, thus emphasizing the potential of this compound as a natural healing agent.
Appendix
Available only for authorised users
Literature
1.
go back to reference Voet D, Voet JG, Pratt C: Fundamentals of Biochemistry. 1999, New York: Wiley Voet D, Voet JG, Pratt C: Fundamentals of Biochemistry. 1999, New York: Wiley
2.
go back to reference Berdel WE, Andreesen R, Murder PG: Synthetic alkyl-phospholipid analogs: A new class of antitumor agents. Phospholipids and Cellular Regulation. Volume 2.1st edition. Edited by: Hyh-Fa K. 1985, CRC Press, 42-73. Berdel WE, Andreesen R, Murder PG: Synthetic alkyl-phospholipid analogs: A new class of antitumor agents. Phospholipids and Cellular Regulation. Volume 2.1st edition. Edited by: Hyh-Fa K. 1985, CRC Press, 42-73.
4.
go back to reference Candal FJ, Bosse DC, Vogler WR, Ades EW: Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother Pharmacol. 1994, 34: 175-178. 10.1007/BF00685937.CrossRefPubMed Candal FJ, Bosse DC, Vogler WR, Ades EW: Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother Pharmacol. 1994, 34: 175-178. 10.1007/BF00685937.CrossRefPubMed
5.
go back to reference Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Busch R, Modest EJ, Noseda A, Rastetter J, Vogler WR, Berdel WE: Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro. Cancer Chemother Pharmacol. 1990, 26: 437-443. 10.1007/BF02994095.CrossRefPubMed Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Busch R, Modest EJ, Noseda A, Rastetter J, Vogler WR, Berdel WE: Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro. Cancer Chemother Pharmacol. 1990, 26: 437-443. 10.1007/BF02994095.CrossRefPubMed
6.
go back to reference Hong CI, West CR, Bernacki RJ, Tebbi CK, Berdel WE: 1-β-D-arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrug with improved antitumor activity. Lipids. 1991, 26: 1437-1444. 10.1007/BF02536582.CrossRefPubMed Hong CI, West CR, Bernacki RJ, Tebbi CK, Berdel WE: 1-β-D-arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrug with improved antitumor activity. Lipids. 1991, 26: 1437-1444. 10.1007/BF02536582.CrossRefPubMed
7.
go back to reference Kára J: Ether-phospholipids in oncology. Chemicke listy. 1993, 87: 58-63. Kára J: Ether-phospholipids in oncology. Chemicke listy. 1993, 87: 58-63.
8.
go back to reference Langen P, Maurer HR, Brachwitz H, Eckert K, Veit A, Vollgraf C: Cytostatic effects of various alkyl phospholipid analogues on different cells in vitro. Anticancer Res. 1992, 12: 2109-2112.PubMed Langen P, Maurer HR, Brachwitz H, Eckert K, Veit A, Vollgraf C: Cytostatic effects of various alkyl phospholipid analogues on different cells in vitro. Anticancer Res. 1992, 12: 2109-2112.PubMed
9.
go back to reference Principe P, Braquet P: Advances in ether phospholipids treatment of cancer. Crit Rev Oncol Hematol. 1995, 18: 155-178. 10.1016/1040-8428(94)00118-D.CrossRefPubMed Principe P, Braquet P: Advances in ether phospholipids treatment of cancer. Crit Rev Oncol Hematol. 1995, 18: 155-178. 10.1016/1040-8428(94)00118-D.CrossRefPubMed
10.
go back to reference Vogler WR, Olson AC, Berdel WE: Comparison of antitumor-activity of 5 ether phospholipids against leukemic- cell lines. P Am Assoc Canc Res. 1988, 29: 321-321. Vogler WR, Olson AC, Berdel WE: Comparison of antitumor-activity of 5 ether phospholipids against leukemic- cell lines. P Am Assoc Canc Res. 1988, 29: 321-321.
11.
go back to reference Noseda A, White JG, Godwin PI, Jerome WG, Modest EJ: Membrane damage in leukemic cells induced by ether and ester lipids: An electron microscopic study. Exp Mol Pathol. 1989, 50: 69-83. 10.1016/0014-4800(89)90057-9.CrossRefPubMed Noseda A, White JG, Godwin PI, Jerome WG, Modest EJ: Membrane damage in leukemic cells induced by ether and ester lipids: An electron microscopic study. Exp Mol Pathol. 1989, 50: 69-83. 10.1016/0014-4800(89)90057-9.CrossRefPubMed
12.
go back to reference Diomede L, Piovani B, Modest EJ, Noseda A, Salmona M: Increased ether lipid cytotoxicity by reducing membrane cholesterol content. Int J Cancer. 1991, 49: 409-413. 10.1002/ijc.2910490317.CrossRefPubMed Diomede L, Piovani B, Modest EJ, Noseda A, Salmona M: Increased ether lipid cytotoxicity by reducing membrane cholesterol content. Int J Cancer. 1991, 49: 409-413. 10.1002/ijc.2910490317.CrossRefPubMed
13.
go back to reference Dymond M, Attard G, Postle AD: Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress. J R Soc Interface. 2008, 5: 1371-1386. 10.1098/rsif.2008.0041.CrossRefPubMedPubMedCentral Dymond M, Attard G, Postle AD: Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress. J R Soc Interface. 2008, 5: 1371-1386. 10.1098/rsif.2008.0041.CrossRefPubMedPubMedCentral
14.
go back to reference Kotyk A, Kára J, Baudyšová M, Knotková A, Drahota Z: Effect of alkyl-phospholipids on mammalian cell permeability. Molecular Aspects of Human Diseases. Volume 1. Edited by: Gorrod JW, Albamo O, Papa S. 1989, Chichestr: Ellis Horwood, 41-43. Kotyk A, Kára J, Baudyšová M, Knotková A, Drahota Z: Effect of alkyl-phospholipids on mammalian cell permeability. Molecular Aspects of Human Diseases. Volume 1. Edited by: Gorrod JW, Albamo O, Papa S. 1989, Chichestr: Ellis Horwood, 41-43.
15.
go back to reference Mikhaevich IS, Gerasimova GK, Kara J: Inhibition of protein kinase C by semisynthetic phospholipid plasmanyl-(N-acyl)-ethanolamine, a nontoxic antitumor preparation. Biochem Int. 1991, 23: 215-220. 10.1016/0020-711X(91)90192-P.CrossRefPubMed Mikhaevich IS, Gerasimova GK, Kara J: Inhibition of protein kinase C by semisynthetic phospholipid plasmanyl-(N-acyl)-ethanolamine, a nontoxic antitumor preparation. Biochem Int. 1991, 23: 215-220. 10.1016/0020-711X(91)90192-P.CrossRefPubMed
16.
go back to reference Zheng B, Oishi K, Shoji M, Eibl H, Berdel WE, Hajdu J, Vogler WR, Kuo JF: Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 1990, 50: 3025-3031.PubMed Zheng B, Oishi K, Shoji M, Eibl H, Berdel WE, Hajdu J, Vogler WR, Kuo JF: Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 1990, 50: 3025-3031.PubMed
17.
go back to reference Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM: Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol. 2007, 30: 785-792.PubMed Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM: Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol. 2007, 30: 785-792.PubMed
18.
go back to reference Sliva D: Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Target. 2004, 4: 327-336. 10.2174/1568009043332961.CrossRef Sliva D: Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Target. 2004, 4: 327-336. 10.2174/1568009043332961.CrossRef
19.
go back to reference Chun JS, Ha MJ, Jacobson BS: Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. J Biol Chem. 1996, 271: 13008-13012. 10.1074/jbc.271.22.13008.CrossRefPubMed Chun JS, Ha MJ, Jacobson BS: Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. J Biol Chem. 1996, 271: 13008-13012. 10.1074/jbc.271.22.13008.CrossRefPubMed
20.
go back to reference Kára J, Borovička M, Liebl V, Smolíková J, Ubik K: A novel nontoxic alkyl-phospholipid with selective antitumor activity, plasmanyl-(IV-acyl)-ethanolamine (PNAE), isolated from degenerating chick embryonal tissues and from an anticancer biopreparation cACPL. Neoplasma. 1986, 33: 187-205.PubMed Kára J, Borovička M, Liebl V, Smolíková J, Ubik K: A novel nontoxic alkyl-phospholipid with selective antitumor activity, plasmanyl-(IV-acyl)-ethanolamine (PNAE), isolated from degenerating chick embryonal tissues and from an anticancer biopreparation cACPL. Neoplasma. 1986, 33: 187-205.PubMed
21.
go back to reference Kára J, Liebl V, Nováček A, Bejšovcová L: A method of a preparation manufacturing with dietetic-preventive and curative effect based on egg 1-O-alkyl-2-acyl phosphatidyl ethanolamines. (In Czech) CZ Patent 282 139. 1997, Prague, Czech Republic: Industrial Property Office Kára J, Liebl V, Nováček A, Bejšovcová L: A method of a preparation manufacturing with dietetic-preventive and curative effect based on egg 1-O-alkyl-2-acyl phosphatidyl ethanolamines. (In Czech) CZ Patent 282 139. 1997, Prague, Czech Republic: Industrial Property Office
22.
go back to reference Kára J, Liebl V, Dědková V, Bejšovcová L: Mode of semisynthetic preparation of plasmanyl-(N-acyl)-ethanolamine (PNAE(s)), alkyl-phospholipid with selective antitumor activity. (In Czech) Czechoslovak patent, PV-08341-87. 1987, Prague, Czech Republic: Industrial Property Office Kára J, Liebl V, Dědková V, Bejšovcová L: Mode of semisynthetic preparation of plasmanyl-(N-acyl)-ethanolamine (PNAE(s)), alkyl-phospholipid with selective antitumor activity. (In Czech) Czechoslovak patent, PV-08341-87. 1987, Prague, Czech Republic: Industrial Property Office
23.
go back to reference Kára J, Konovalova AL, Krasnova MA, Liebl V, Bejšovcová L: New tumoricidal semisynthetic ether phospholipid, plasmanyl-(N-acyl)ethanolamine (PNAE(s)) and enhancement of its tumoricidal activity by calcium ions. Neoplasma. 1993, 40: 213-217.PubMed Kára J, Konovalova AL, Krasnova MA, Liebl V, Bejšovcová L: New tumoricidal semisynthetic ether phospholipid, plasmanyl-(N-acyl)ethanolamine (PNAE(s)) and enhancement of its tumoricidal activity by calcium ions. Neoplasma. 1993, 40: 213-217.PubMed
24.
go back to reference Kára J, Zimakova NI, Serebryakova EA, Dědková V, Zolotaryov AF: Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine in mice bearing sarcoma Mc11. J Cancer Res Clin Oncol. 1994, 120: 662-667. 10.1007/BF01245378.CrossRefPubMed Kára J, Zimakova NI, Serebryakova EA, Dědková V, Zolotaryov AF: Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine in mice bearing sarcoma Mc11. J Cancer Res Clin Oncol. 1994, 120: 662-667. 10.1007/BF01245378.CrossRefPubMed
25.
go back to reference Krejci J, Nechvatalova K, Kudlackova H, Faldyna M, Kucerova Z, Toman M: Systemic and local antibody responses after experimental infection with Actinobacillus pleuropneumoniae in piglets with passive or active immunity. J Vet Med B Infect Dis Vet Public Health. 2005, 52: 190-196. 10.1111/j.1439-0450.2005.00844.x.CrossRefPubMed Krejci J, Nechvatalova K, Kudlackova H, Faldyna M, Kucerova Z, Toman M: Systemic and local antibody responses after experimental infection with Actinobacillus pleuropneumoniae in piglets with passive or active immunity. J Vet Med B Infect Dis Vet Public Health. 2005, 52: 190-196. 10.1111/j.1439-0450.2005.00844.x.CrossRefPubMed
26.
go back to reference Bernardy J, Nechvatalova K, Krejci J, Kudlackova H, Brazdova I, Kucerova Z, Faldyna M: Comparison of different doses of antigen for intradermal administration in pigs: the Actinobacillus pleuropneumoniae model. Vaccine. 2008, 26: 6368-6372. 10.1016/j.vaccine.2008.09.027.CrossRefPubMed Bernardy J, Nechvatalova K, Krejci J, Kudlackova H, Brazdova I, Kucerova Z, Faldyna M: Comparison of different doses of antigen for intradermal administration in pigs: the Actinobacillus pleuropneumoniae model. Vaccine. 2008, 26: 6368-6372. 10.1016/j.vaccine.2008.09.027.CrossRefPubMed
27.
go back to reference Gladkowski W, Chojnacka A, Kielbowicz G, Trziszka T, Wawrzenczyk C: Isolation of Pure Phospholipid Fraction from Egg Yolk. J Am Oil Chem Soc. 2012, 89: 179-182. 10.1007/s11746-011-1893-x.CrossRef Gladkowski W, Chojnacka A, Kielbowicz G, Trziszka T, Wawrzenczyk C: Isolation of Pure Phospholipid Fraction from Egg Yolk. J Am Oil Chem Soc. 2012, 89: 179-182. 10.1007/s11746-011-1893-x.CrossRef
28.
go back to reference Vojkovsky T, Liebl V: N-acylované fosfolipidy typu 1-O-alkyl-sn-glycero-3-fosfoethanolaminů, způsob jejich semisyntetické přípravy a použití. (In Czech) CZ Patent 280 686. 1996, Prague, Czech Republic: Industrial Property Office Vojkovsky T, Liebl V: N-acylované fosfolipidy typu 1-O-alkyl-sn-glycero-3-fosfoethanolaminů, způsob jejich semisyntetické přípravy a použití. (In Czech) CZ Patent 280 686. 1996, Prague, Czech Republic: Industrial Property Office
29.
go back to reference Nechvatalova K, Knotigova P, Krejci J, Faldyna M, Gopfert E, Satran P, Toman M: Significance of different types and levels of antigen specific immunity to Actinobacillus pleuropneumoniae infection in piglets. Vet. Med. - Czech. 2005, 50: 47-59. Nechvatalova K, Knotigova P, Krejci J, Faldyna M, Gopfert E, Satran P, Toman M: Significance of different types and levels of antigen specific immunity to Actinobacillus pleuropneumoniae infection in piglets. Vet. Med. - Czech. 2005, 50: 47-59.
30.
go back to reference Stepanova H, Pavlova B, Stromerova N, Ondrackova P, Stejskal K, Slana I, Zdrahal Z, Pavlik I, Faldyna M: Different immune response of pigs to Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis infection. Vet Microbiol. 2012, 159: 343-350. 10.1016/j.vetmic.2012.04.002.CrossRefPubMed Stepanova H, Pavlova B, Stromerova N, Ondrackova P, Stejskal K, Slana I, Zdrahal Z, Pavlik I, Faldyna M: Different immune response of pigs to Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis infection. Vet Microbiol. 2012, 159: 343-350. 10.1016/j.vetmic.2012.04.002.CrossRefPubMed
31.
go back to reference Pavlova B, Volf J, Ondrackova P, Matiasovic J, Stepanova H, Crhanova M, Karasova D, Faldyna M, Rychlik I: SPI-1-encoded type III secretion system of Salmonella enterica is required for the suppression of porcine alveolar macrophage cytokine expression. Vet Res. 2011, 42: 16-10.1186/1297-9716-42-16.CrossRefPubMedPubMedCentral Pavlova B, Volf J, Ondrackova P, Matiasovic J, Stepanova H, Crhanova M, Karasova D, Faldyna M, Rychlik I: SPI-1-encoded type III secretion system of Salmonella enterica is required for the suppression of porcine alveolar macrophage cytokine expression. Vet Res. 2011, 42: 16-10.1186/1297-9716-42-16.CrossRefPubMedPubMedCentral
32.
go back to reference Volf J, Boyen F, Faldyna M, Pavlova B, Navratilova J, Rychlik I: Cytokine response of porcine cell lines to Salmonella enterica serovar Typhimurium and its hilA and ssrA mutants. Zoonoses Public Health. 2007, 54: 286-293. 10.1111/j.1863-2378.2007.01064.x.CrossRefPubMed Volf J, Boyen F, Faldyna M, Pavlova B, Navratilova J, Rychlik I: Cytokine response of porcine cell lines to Salmonella enterica serovar Typhimurium and its hilA and ssrA mutants. Zoonoses Public Health. 2007, 54: 286-293. 10.1111/j.1863-2378.2007.01064.x.CrossRefPubMed
33.
go back to reference Meurens F, Berri M, Auray G, Melo S, Levast B, Virlogeux-Payant I, Chevaleyre C, Gerdts V, Salmon H: Early immune response following Salmonella enterica subspecies enterica serovar Typhimurium infection in porcine jejunal gut loops. Vet Res. 2009, 40: 5-10.1051/vetres:2008043.CrossRefPubMed Meurens F, Berri M, Auray G, Melo S, Levast B, Virlogeux-Payant I, Chevaleyre C, Gerdts V, Salmon H: Early immune response following Salmonella enterica subspecies enterica serovar Typhimurium infection in porcine jejunal gut loops. Vet Res. 2009, 40: 5-10.1051/vetres:2008043.CrossRefPubMed
34.
go back to reference Kyrova K, Stepanova H, Rychlik I, Faldyna M, Volf J: SPI-1 encoded genes of Salmonella Typhimurium influence differential polarization of porcine alveolar macrophages in vitro. Vet Res. 2012, 8: 115- Kyrova K, Stepanova H, Rychlik I, Faldyna M, Volf J: SPI-1 encoded genes of Salmonella Typhimurium influence differential polarization of porcine alveolar macrophages in vitro. Vet Res. 2012, 8: 115-
35.
go back to reference Nygard AB, Jorgensen CB, Cirera S, Fredholm M: Selection of reference genes for gene expression studies in pig tissues using SYBR green qPCR. BMC Mol Biol. 2007, 8: 67-10.1186/1471-2199-8-67.CrossRefPubMedPubMedCentral Nygard AB, Jorgensen CB, Cirera S, Fredholm M: Selection of reference genes for gene expression studies in pig tissues using SYBR green qPCR. BMC Mol Biol. 2007, 8: 67-10.1186/1471-2199-8-67.CrossRefPubMedPubMedCentral
36.
go back to reference Zelnickova P, Matiasovic J, Pavlova B, Kudlackova H, Kovaru F, Faldyna M: Quantitative nitric oxide production by rat, bovine and porcine macrophages. Nitric Oxide. 2008, 19: 36-41.CrossRefPubMed Zelnickova P, Matiasovic J, Pavlova B, Kudlackova H, Kovaru F, Faldyna M: Quantitative nitric oxide production by rat, bovine and porcine macrophages. Nitric Oxide. 2008, 19: 36-41.CrossRefPubMed
37.
go back to reference Motulsky HJ: Analyzing Data with GraphPad Prism. 1999, San Diego CA: GraphPad Software Inc. Motulsky HJ: Analyzing Data with GraphPad Prism. 1999, San Diego CA: GraphPad Software Inc.
38.
go back to reference Herrmann R, Berdel WE: Therapeutic activity of a thioether-lipid conjugate of 1-beta-D-arabinofuranosylcytosine in human colorectal cancer xenografts. Cancer Res. 1992, 52: 1865-1867.PubMed Herrmann R, Berdel WE: Therapeutic activity of a thioether-lipid conjugate of 1-beta-D-arabinofuranosylcytosine in human colorectal cancer xenografts. Cancer Res. 1992, 52: 1865-1867.PubMed
39.
go back to reference Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, Jourdan ML, LeGuennec JY, Bougnoux P, Vandier C: The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011, 162: 464-479. 10.1111/j.1476-5381.2010.01044.x.CrossRefPubMedPubMedCentral Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, Jourdan ML, LeGuennec JY, Bougnoux P, Vandier C: The SK3/KCa2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011, 162: 464-479. 10.1111/j.1476-5381.2010.01044.x.CrossRefPubMedPubMedCentral
40.
go back to reference Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA, Martinez JA: Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 2009, 58: 537-552. 10.1007/s00011-009-0037-3.CrossRefPubMed Garcia-Lafuente A, Guillamon E, Villares A, Rostagno MA, Martinez JA: Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 2009, 58: 537-552. 10.1007/s00011-009-0037-3.CrossRefPubMed
41.
go back to reference Shin JS, Park YM, Choi JH, Park HJ, Shin MC, Lee YS, Lee KT: Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-kappa B in RAW 264.7 murine macrophage cells. Int Immunopharmacol. 2010, 10: 943-950. 10.1016/j.intimp.2010.05.007.CrossRefPubMed Shin JS, Park YM, Choi JH, Park HJ, Shin MC, Lee YS, Lee KT: Sulfuretin isolated from heartwood of Rhus verniciflua inhibits LPS-induced inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines expression via the down-regulation of NF-kappa B in RAW 264.7 murine macrophage cells. Int Immunopharmacol. 2010, 10: 943-950. 10.1016/j.intimp.2010.05.007.CrossRefPubMed
42.
go back to reference Joung EJ, Lee MS, Choi JW, Kim JS, Shin T, Jung BM, Yoon NY, Lim CW, Kim JI, Kim HR: Anti-inflammatory effect of ethanolic extract from Myagropsis myagroides on murine macrophages and mouse ear edema. BMC Complem Altern M. 2012, 12: 171-10.1186/1472-6882-12-171.CrossRef Joung EJ, Lee MS, Choi JW, Kim JS, Shin T, Jung BM, Yoon NY, Lim CW, Kim JI, Kim HR: Anti-inflammatory effect of ethanolic extract from Myagropsis myagroides on murine macrophages and mouse ear edema. BMC Complem Altern M. 2012, 12: 171-10.1186/1472-6882-12-171.CrossRef
43.
go back to reference Kim IT, Park YM, Shin KM, Ha J, Choi J, Jung HJ, Park HJ, Lee KT: Anti-inflammatory and anti-nociceptive effects of the extract from Kalopanax pictus, Pueraria hunbergiana and Rhus vemiciflua. J Ethnopharmacol. 2004, 94: 165-173. 10.1016/j.jep.2004.05.015.CrossRefPubMed Kim IT, Park YM, Shin KM, Ha J, Choi J, Jung HJ, Park HJ, Lee KT: Anti-inflammatory and anti-nociceptive effects of the extract from Kalopanax pictus, Pueraria hunbergiana and Rhus vemiciflua. J Ethnopharmacol. 2004, 94: 165-173. 10.1016/j.jep.2004.05.015.CrossRefPubMed
44.
go back to reference Talmadge JE, Schneider M, Lenz B, Phillips H, Long C: Immunomodulatory and therapeutic properties of alkyl-lysophospholipids in mice. Lipids. 1987, 22: 871-877. 10.1007/BF02535547.CrossRefPubMed Talmadge JE, Schneider M, Lenz B, Phillips H, Long C: Immunomodulatory and therapeutic properties of alkyl-lysophospholipids in mice. Lipids. 1987, 22: 871-877. 10.1007/BF02535547.CrossRefPubMed
45.
go back to reference Ngwenya BZ, Fiavey NP, Mogashoa MM: Activation of peritoneal macrophages by orally administered ether analogues of lysophospholipids. Proc Soc Exp Biol Med. 1991, 97: 91-97.CrossRef Ngwenya BZ, Fiavey NP, Mogashoa MM: Activation of peritoneal macrophages by orally administered ether analogues of lysophospholipids. Proc Soc Exp Biol Med. 1991, 97: 91-97.CrossRef
46.
go back to reference Brinkmann G, Molnar S: Influence of dietary fats and lecithins on parameters of defence against infection in weaned pigs; 2nd communication: Influence of soy or egg lecithin. Fett-Lipid. 1998, 100: 16-20. 10.1002/lipi.200690050.CrossRef Brinkmann G, Molnar S: Influence of dietary fats and lecithins on parameters of defence against infection in weaned pigs; 2nd communication: Influence of soy or egg lecithin. Fett-Lipid. 1998, 100: 16-20. 10.1002/lipi.200690050.CrossRef
47.
Metadata
Title
Evaluation of in vitro and in vivo anti-inflammatory activity of biologically active phospholipids with anti-neoplastic potential in porcine model
Authors
Monika Vicenova
Katerina Nechvatalova
Katarina Chlebova
Zdenka Kucerova
Lenka Leva
Hana Stepanova
Martin Faldyna
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-14-339

Other articles of this Issue 1/2014

BMC Complementary Medicine and Therapies 1/2014 Go to the issue